30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

Revenue Review: 1H18 Growth and 2Q18 Performance Highlights for Public Companies

The 21 companies we track collectively grew +3.6% in 1H18 vs. 1H17—still on pace to reach our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017.

Public Orthopaedic Companies: 1Q18 Revenue and Growth Drivers

Alongside their 1Q18 results, numerous players reaffirmed or updated their full-year revenue guidance. Globus Medical increased its numbers based on adoption of ExcelsiusGPS, K2M grew its range by $3MM following a distributor partnership and Orthofix upped guidance by about $9MM in acquisition-related contributions. After the quarter’s close, Wright Medical announced FDA premarket approval for AUGMENT injectable bone graft, and will update its full-year guidance in the 2Q18 call.

Majority of Public Orthopaedic Companies Still on Track for Full-Year Guidance

Following weather events, oft-cited “softness” in U.S. spine procedures (to wit: volume is reportedly low this year) and the enactment of a price ceiling on knee devices in India, some—like ConforMIS, ConMed, DePuy Synthes, Exactech, Integra, K2M and Stryker—noted modest reductions in revenue.

Sales Results for 20 Orthopaedic Companies: A Mid-year Status Report

Now that we’ve collected 1H17 results from 20 publicly-traded companies, I’d like to share some performance-based observations. With just 4 months remaining in the year, these companies provide a helpful gauge in projecting industry growth.

DePuy Synthes Company Profile

DePuy Synthes ranks as the largest player in orthopaedics by revenue, accounting for 18% of the total orthopaedic market, according to ORTHOWORLD estimates. The company posted 2016 revenue of $9,003.5 million, +0.8% vs. 2015.

Page Navigation